Menu
Search
|

Menu

Close
X

Restorbio Inc TORC.OQ (NASDAQ Stock Exchange Global Select Market)

10.55 USD
-0.31 (-2.85%)
As of 2:17 PM EDT
chart
Previous Close 10.86
Open 10.87
Volume 12,315
3m Avg Volume 38,801
Today’s High 11.38
Today’s Low 10.45
52 Week High 21.09
52 Week Low 7.62
Shares Outstanding (mil) 28.05
Market Capitalization (mil) 307.67
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.458
FY17
-1.959
FY16
0.000
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.04
Price to Sales (TTM)
vs sector
--
8.22
Price to Book (MRQ)
vs sector
2.34
4.29
Price to Cash Flow (TTM)
vs sector
--
22.60
Total Debt to Equity (MRQ)
vs sector
0.00
17.61
LT Debt to Equity (MRQ)
vs sector
0.00
13.12
Return on Investment (TTM)
vs sector
--
13.11
Return on Equity (TTM)
vs sector
--
15.11

EXECUTIVE LEADERSHIP

Chen Schor
President, Chief Executive Officer, Co-Founder, Director, Since
Salary: --
Bonus: --
Joan Mannick
Co-Founder, Chief Medical Officer & Director, Since
Salary: --
Bonus: --
John McCabe
Vice President - Finance, Since
Salary: --
Bonus: --
Sarb Shergill
Vice President - Clinical Operations, Since
Salary: --
Bonus: --
Susan Stewart
Head of Regulatory Affairs, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

500 Boylston St Fl 12
BOSTON   MA   02116-3740

Phone: +1617.4822333

resTORbio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. It focuses on the mechanistic target of rapamycin (mTOR) pathway that regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1 (TORC1). Its initial focus is on the development of RTB101, an orally administered, small molecule, potent TORC1 inhibitor, alone and in combination with other mTOR inhibitors, such as everolimus. Its product pipeline includes the TORC1 program that includes the development of RTB101 for various indications. The indications include respiratory tract infections, heart failure with preserved ejection fraction, autophagy related neurodegenerative diseases and other indications. The Company is developing RTB101 in a Phase II b clinical trial.

SPONSORED STORIES